Takeover Is Rx For tPA Blues At Genentech

Analysts say the Roche deal blunts the impact of a report in which the firm's top product fares poorly against its competition Genentech took it on the chin last month when a massive study by Italian scientists found that tPA, tissue plasminogen activator, was no more effective in treating heart attacks than streptokinase, a bacterial enzyme that costs one tenth as much. But the stock price of the South San Francisco, Calif., company, which manufactures the drug, hardly budged. Although tPA i

Written byLisa Bain

| 5 min read

Save for Later

Listen with Speechify

0:00

5:00

Analysts say the Roche deal blunts the impact of a report in which the firm's top product fares poorly against its competition

Genentech took it on the chin last month when a massive study by Italian scientists found that tPA, tissue plasminogen activator, was no more effective in treating heart attacks than streptokinase, a bacterial enzyme that costs one tenth as much.

But the stock price of the South San Francisco, Calif., company, which manufactures the drug, hardly budged. Although tPA is Genen-tech's leading product, accounting for $196 million of the company's $319 million total sales in 1989, Wall Street responded to the announcement with a mere $1.125 per share drop in stock price, closing that day at $26.125. Over the next few days, the stock held fairly steady, registering a total loss of about 2 1/2 points.

Wall Street's relatively weak reaction to the tPA announcement is viewed by ...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!

Join for free today

Already a member?